Investor Watch | Psilocybin Innovation Takes Off – Startups, Trials, and Policy Breakthroughs

“The Magic Mushroom” – or its key ingredient, Psilocybin – appears to be out in the lead in the modern wave of psychedelic research. Alongside the high-profile Phase II trial results from Compass Pathways (CMPS, profiled previously on TrialSite News), a handful of other early studies are progressing, or close to starting: Usona Institute, Filament Health, Numinus (NUMI), Diamond Therapeutics, TheraPsil.


Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee